Generate a tailored SOP for Dr. Pinelopi Manousou. Improve your application with a focused, well-structured draft.
Pinelopi Manousou is a clinical translational hepatologist and Professor of Practice at Imperial College London, specializing in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), liver fibrosis, and microbiome-based therapies. She leads the MASLD Service at Imperial College Healthcare NHS Trust and serves as the Chief Investigator on several academic and industry-funded clinical studies, including the Eli Lilly Phase II tirzepatide study in MASH and the Novo Nordisk–Parexel MARC1 study. Additionally, Dr. Manousou is the National Lead Investigator for the 89Bio pegozafermin study in NASH and Principal Investigator for six further MASLD clinical studies. Her research program intersects the metabolic and viral components of chronic hepatitis B and MASLD, exploring microbiome-targeted interventions, digital AI-based quantification of liver fibrosis, and senolytic therapies for MASLD. With over 110 peer-reviewed publications in prominent journals like The Lancet and Nature Medicine, she has garnered more than 10,000 citations. Dr. Manousou has served on the Board of Directors at the University of Ioannina and holds various roles within professional associations, emphasizing her commitment to advancing liver disease research.
Specialisms available in Materials for the Energy Transition or Theory and Simulation of Materials.